Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

455 results
Display

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study

Lee SK, Lee SW, Lee HL, Kim HY, Kim CW, Song DS, Chang UI, Yang JM, Yoo SH, Kwon JH, Nam SW, Kim SH, Song MJ, Lee J, Yang H, Bae SH, Han JW, Nam H, Sung PS, Jang JW, Choi JY, Yoon SK

Background/Aims: To evaluate the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) therapy in hepatitis C virus (HCV)-infected Korean patients in a real clinical setting. Methods: A total of 273 patients who received...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and Treatment

Choi J, Park J, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Chung YH

Background/Aims: The care cascade for hepatitis C virus (HCV) infection is impeded by multiple barriers, including suboptimal anti-HCV testing, link to care, and diagnosis. We explored the changes in the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Features of Hepatitis C Virus-related Acute-on-chronic Liver Failure in a Korean Population

Choi JW, Kwak JY, Lee SS, Kim Hg, Son HJ, Jeon H, Kim HJ, Cha RR, Lee JM, Kim HJ

Background/Aims: Acute-on-chronic liver failure (ACLF) is a widely recognized concept in which acute decompensation (AD) in patients with cirrhosis results in organ failure and high short-term mortality. On the other...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Assessing the Effectiveness and Safety of Direct-acting Antiviral Treatment in Korean Patients with Hepatitis C Virus Genotype 1b or 2 at a Tertiary Care Hospital

Park MS, Yang YM, Park KH, Yoon H, Kim JS, Choi EJ

Background: Direct-acting antivirals are recommended for the treatment of chronic hepatitis C virus in Korea. However, evaluation of direct-acting antiviral regimens in a real-world setting is limited. The aims of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease

Ryu JE, Song MJ, Kim SH, Kwon JH, Yoo SH, Nam SW, Nam HC, Kim HY, Kim CW, Yang H, Bae SH, Song DS, Chang UI, Yang JM, Lee SW, Lee HL, Lee SK, Sung PS, Jang JW, Choi JY, Yoon SK

Background/Aims: To evaluate the effectiveness and safety of direct acting antivirals (DAAs) available in chronic kidney disease (CKD) patients with hepatitis C virus (HCV) infection in Korea. Methods: In a retrospective,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment

Ahn YH, Lee H, Han JE, Cho HJ, Cheong JY, Park B, Kim SS

Background/Aim: There has been a long-standing debate about the association of directacting antiviral (DAA) therapy and hepatocellular carcinoma (HCC) recurrence. This study aimed to investigate the association between DAA therapy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Viral Hepatitis in Patients with Inflammatory Bowel Disease

Shin SH, Park SH

There has been a rise in the incidence of inflammatory bowel disease (IBD) in developing countries, including South Korea. Consequently, the use of immunosuppressive agents such as immunomodulators or biologics...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The impact of nucleic acid testing as a blood donor screening method in transfusion-associated hepatitis C among children with bleeding disorders in Indonesia: a single-center experience

Chozie NA, Satiti MA, Sjarif DR, Oswari H, Ritchie NK

Background Children with bleeding disorders, such as hemophilia and von Willebrand disease (VWD), have an increased risk of acquiring transfusion-transmitted infections (TTI). Screening methods to exclude blood donations that are at...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatitis B, C, and D Virus Infections and AFP Tumor Marker Prevalence Among the Elderly Population in Mongolia: A Nationwide Survey

Dambadarjaa D, Mukhtar Y, Tsogzolbaatar EO, Khuyag SO, Dayan A, Oyunbileg NE, Shagdarsuren OE, Nyam G, Yosikazu N, Takahashi M, Okamoto H

Objectives: Infections with hepatitis B, C, and D virus (HBV, HCV, and HDV) are a major public health problem and lead to serious complications such as cirrhosis and hepatocellular carcinoma....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cost-effectiveness of chronic hepatitis C screening and treatment

Lee HW, Lee H, Kim BK, Chang Y, Jang JY, Kim DY

Hepatitis C virus (HCV) infection is the second most common cause of chronic liver disease in South Korea, with a prevalence ranging from 0.6% to 0.8%, and HCV infection incidence...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective

Kim HL, Kim KA, Choi GH, Jang ES, Ki M, Choi HY, Jeong SH

Background/Aims: This study aimed to evaluate the cost-effectiveness of hepatitis C virus (HCV) screening compared to no screening in the Korean population from societal and healthcare system perspectives. Methods: A published...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials

Heo J, Kim YJ, Lee JW, Kim JH, Lim YS, Han KH, Jeong SH, Cho M, Yoon KT, Bae SH, Crown ED, Fredrick LM, Alami NN, Asatryan A, Kim DH, Paik SW, Lee YJ

Background/Aims: Glecaprevir/pibrentasvir (G/P) is the first pan-genotypic direct-acting antiviral combination therapy approved in Korea. An integrated analysis of five phase II and III trials was conducted to evaluate the efficacy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea

Lim DH, Jeong JY, Nam S, Choi J, Kwon HC, Yoon YB, Kim Y, Chin B

Background: Because of the very low incidence of human immunodeficiency virus (HIV) coinfection in Korea, data on hepatitis C virus (HCV)/HIV coinfection are limited. This study aimed to investigate the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination

Brunner N, Bruggmann P

Hepatitis C infection is responsible for high morbidity and mortality rates globally as well as for significant indirect costs. The disease burden caused by the hepatitis C virus (HCV) is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients

Wong YJ, Thurairajah PH, Kumar R, Fock KM, Law NM, Chong SY, Manejero FG, Ang TL, Teo EK, Tan J

Background/Aims: Despite the disproportionally high prevalence rates of hepatitis C virus (HCV) amongst the incarcerated population, eradication remains challenging due to logistic and financial barriers. Although treatment prioritization based on...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study

Kang YW, Baek YH, Lee SW, Park SJ, Yoon JS, Yoon KT, Hong Y, Heo NY, Seo KI, Lee SS, Cho HC, Shin JW

Background: The advancement of treatment with direct-acting antiviral (DAA) agents has improved the cure rate of hepatitis C virus (HCV) infection close to 100%. The aim of our study was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C

Ahn YH, Lee H, Kim DY, Lee HW, Yu SJ, Cho YY, Jang JW, Jang BK, Kim CW, Kim HY, Park H, Cho HJ, Park B, Kim SS, Cheong JY

Background/Aims: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution

Park YJ, Woo HY, Heo J, Park SG, Hong YM, Yoon KT, Kim DU, Kim GH, Kim HH, Song GA, Cho M

Background/Aims: Glecaprevir/pibrentasvir (G/P) is a combination of direct-acting antiviral agents that is an approved treatment for chronic infections by all six hepatitis C virus (HCV) genotypes. However, there are limited...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2

Han SY, Woo HY, Heo J, Park SG, Pyeon SI, Park YJ, Kim DU, Kim GH, Kim HH, Song GA, Cho M

Background/Aims: Real-world, clinical practice data are lacking about sofosbuvir/ ribavirin (SOF/RBV) treatment of Korean patients with hepatitis C virus genotype 2 (HCV GT2) infection. This study investigated the efficacy and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Analysis of Results of Liver-related Health Care Checkup in Mongolian Immigrants: A Comparison with Results from Koreans

Kim DH, Lee JK, Kim H, Oh Ac, Hong YJ, Park SC, Kong CB

Background: The incidence and mortality rate of liver cancer in Mongolians are known to be the highest in the world, and liver cancer in Mongolians is mainly caused by chronic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr